Search results
Results from the WOW.Com Content Network
Biomarkers are usually required to aid the selection of patients who will likely respond to a given targeted therapy. [6] Co-targeted therapy involves the use of one or more therapeutics aimed at multiple targets, for example PI3K and MEK, in an attempt to generate a synergistic response [5] and prevent the development of drug resistance. [7] [8]
The therapeutic targets in TTD are categorized into successful target, clinical trial target, preclinical target, patented target, and literature-reported target, which are defined by the highest status of their corresponding drugs. Successful target: targeted by at least one approved drug;
This is a list of chemotherapeutic agents, also known as cytotoxic agents or cytostatic drugs, that are known to be of use in chemotherapy for cancer.This list is organized by type of agent, although the subsections are not necessarily definitive and are subject to revision.
Therapeutic target may refer to: Biological target, a protein or nucleic acid whose activity can be modified by an external stimulus; Therapeutic Targets Database, a database to provide information about the known and explored therapeutic targets; Therapeutic target range, an alternative reference range
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
It also included information on 2133 drug targets. The second version of DrugBank was released in 2009. [2] This greatly expanded and improved version of the database included 1344 approved small molecule drugs and 123 biotech drugs as well as 3037 unique drug targets.
This combination therapy leads to increased infiltration and activation of T cells within tumors, the generation of memory T cells, and improved overall survival in both animal models and patients. Notably, this approach has demonstrated efficacy in melanoma and renal carcinoma patients.
Checkpoint inhibitor therapy is a form of cancer immunotherapy. The therapy targets immune checkpoints, key regulators of the immune system that when stimulated can dampen the immune response to an immunologic stimulus. Some cancers can protect themselves from attack by stimulating immune checkpoint targets.